Janssen-Cilag Pty Ltd.

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are:
to investigate whether Esketamine is effective when added to ongoing antidepressant treatment
to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice
Participants will:
attend the clinic for supervised self-administration of intranasal Esketamine treatment
be observed for 2 hours following Esketamine administration including blood pressure monitoring
be asked to complete a battery of questionnaires
be reimbursed for travel expenses

The primary objective of this study is to determine if Australian patients with schizophrenia treated with paliperidone palmitate under conditions of continuous monitoring of outcomes over a 12-month period achieve relapse rates comparable to published literature.